Scarica l'app Stockscreener
4.00
2.44%
-0.10
Dopo l'orario di chiusura:
4.05
0.05
+1.25%
Precedente Chiudi:
$4.10
Aprire:
$4.12
Volume 24 ore:
392.74K
Relative Volume:
0.34
Capitalizzazione di mercato:
$143.94M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-2.1164
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
-6.98%
1M Prestazione:
+36.05%
6M Prestazione:
+94.17%
1 anno Prestazione:
+247.83%
Intervallo 1D:
$4.00
$4.25
Intervallo di 1 settimana:
$3.95
$4.35
Portata 52W:
$1.00
$4.60
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Confronta IMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.00 | 151.86M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
What analysts say about Immuneering Corporation stockFree Stock Market Return Analysis - Autocar Professional
What drives Immuneering Corporation stock priceFastest-growing stock picks - jammulinksnews.com
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Target Price at $13.25 - Defense World
Is Immuneering Corporation a good long term investmentSuperior stock growth - jammulinksnews.com
What makes Immuneering Corporation stock price move sharplyTop Gaining Low Risk Assets - Newser
Why Immuneering Corporation stock attracts strong analyst attentionShort Term Profit Focus - Newser
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - Quantisnow
Revolutionary Cancer Drug Gets Patent Protection Until 2042: Clinical Data Shows 94% Survival vs 67% Standard Care - Stock Titan
Immuneering director Hausman buys IMRX stock worth $19,862 By Investing.com - Investing.com South Africa
Immuneering (IMRX) chief people officer Neufeld buys $2498 in stock By Investing.com - Investing.com South Africa
Immuneering director Hausman buys IMRX stock worth $19,862 - Investing.com
Insider Buying: Thomas Schall Acquires Additional Shares of Immu - GuruFocus
Immuneering (IMRX) Soars 10.66% on Positive Trial Data, Insider Buying - AInvest
At $3.02 Price, Immuneering Corp (IMRX) Is Sitting And Waiting - Stocksregister
Jefferies raises Immuneering price target to $3.50 from $1.50 on cancer data - Investing.com
Insider Buying: Brett Hall Acquires Additional Shares of Immuneering Corp (IMRX) - GuruFocus
Immuneering (IMRX) CBO Brakewood buys $4804 in shares - Investing.com
Immuneering (IMRX) director Feinberg buys $63k in shares - Investing.com
Immuneering (IMRX) CEO Zeskind buys $50k+ in shares By Investing.com - Investing.com UK
Immuneering (NASDAQ:IMRX) Receives Buy Rating from Needham & Company LLC - Defense World
Immuneering (IMRX) Target Price Raised by Mizuho Analyst | IMRX Stock News - GuruFocus
Chardan Capital Maintains Buy Rating on IMRX with $13 Price Targ - GuruFocus
Metric Deep Dive: Understanding La Rosa Holdings Corp (LRHC) Through its Ratios - DWinneX
Financial Analysis: TNL Mediagene (TNMG)’s Ratios Unveil Key Insights - DWinneX
Immuneering (IMRX) Price Target Raised by Mizuho Following Positive Trial Data | IMRX Stock News - GuruFocus
Immuneering stock price target raised to $10 at Mizuho on cancer drug data - Investing.com
Immuneering’s Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - Investing.com India
Immuneering's Positive Pancreatic Cancer Trial Data Sparks Bullish Retail Sentiment Even As Profit-Taking Cools Rally - MENAFN.com
Immuneering’s atebimetinibin shows positive survival data in pancreatic cancer - TipRanks
Immuneering stock rises after positive pancreatic cancer trial data - Investing.com
Immuneering (IMRX) Reports Promising Phase 2a Trial Results for Pancreatic Cancer Treatment | IMRX Stock News - GuruFocus
Pancreatic Cancer Breakthrough: New Drug Shows 94% Survival Rate vs 67% Standard Care in Phase 2a Trial - Stock Titan
Immuneering Stock Soars 25.74% on Promising Cancer Trial Results - AInvest
Immuneering Corp holds annual stockholder meeting By Investing.com - Investing.com Canada
Immuneering Corp holds annual stockholder meeting - Investing.com Australia
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - The Manila Times
Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 - GlobeNewswire Inc.
Two Sigma Investments LP Purchases 10,126 Shares of Immuneering Co. (NASDAQ:IMRX) - Defense World
Immuneering Co. (NASDAQ:IMRX) Stock Position Reduced by Millennium Management LLC - Defense World
Immuneering’s (IMRX) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
Needham Maintains Buy Rating on IMRX with Price Target of $9.00 - GuruFocus
Full Immuneering Leadership Team Reveals Latest Pipeline Updates at Prestigious Jefferies Conference - Stock Titan
Immuneering Corporation to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
‘Take the Plunge,’ Says Top Investor About Intel Stock - The Globe and Mail
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.0 - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst - GuruFocus
Immuneering (IMRX) Price Target Adjusted by Oppenheimer Analyst | IMRX Stock News - GuruFocus
21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP - Defense World
Oppenheimer Adjusts Price Target for Immuneering (IMRX) to $21.00 | IMRX Stock News - GuruFocus
Immuneering Corp. Reports Promising Q1 2025 Results - TipRanks
Immuneering (IMRX) Stock Rating and Price Target Update | IMRX S - GuruFocus
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):